asks the vampire squid (goldman sachs)
..............................................................................................................................................................................
- Analyst Salveen Richter and colleagues laid it out: "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
That was a bad thing to say.
A lot of people already consider GoldMan Sachs to be the devil incarnate. More people will now. Those people vote.
Perhaps it's time to break up GoldMan Sachs? It's bigger than Amazon and there is serious talk about breaking up Amazon.